Utama › Kanser Payudara › Montana
Kajian klinikal Kanser Payudara di Montana
13 kajian untuk Kanser Payudara sedang mencari peserta di lokasi di Montana.
Bandar di Montana
Teks kajian rasmi (Bahasa Inggeris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Intermountain Healthcare, Billings
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- dan 7 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07007559Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06797635A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
Mengambil pesertaFasa 1
Umur 18 hingga 55 · Wanita · Dikemas kini 9 Sep 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926Integrated Cancer Repository for Cancer Research
- Bozeman Health Deaconess Hospital, Bozeman
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- SCL Health - Cancer Centers of Montana, Billings
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT06757634De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 50 hingga 70 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- dan 5 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
- University of Montana, Missoula
Mengambil pesertaFasa 2
Umur 18 hingga 89 · Semua jantina · Dikemas kini 5 Feb 2026 · NCT07001241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Okt 2025 · NCT03418961Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.